Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Lisata Therapeutics Inc. | Certepetide (LSTA1) - (BOLSTER) | Intrahepatic Cholangiocarcinoma | Phase 2a | Ongoing | Intravenous | Oncology |
| Lisata Therapeutics Inc. | LSTA1 in combination with SoC chemotherapy - (BOLSTER) | Solid Tumors | Phase 2a | Ongoing | Intravenous | Oncology |
| Lisata Therapeutics Inc. | LSTA1 | Glioblastoma multiforme (GBM) | Phase 2a | Enrollment Initiation | Intravenous | Oncology |
| Lite Strategy Inc. | Eganelisib + pembrolizumab - (MARIO-8) | Squamous Cell Carcinoma of the Head and Neck (SSCHN) | Phase 2 | Ongoing | Intravenous | Oncology |
| Lite Strategy Inc. | Zandelisib - (MIRAGE) | Indolent B-cell Non-Hodgkin's Lymphoma (iB-NHL) without small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), and Waldenström's macroglobulinemia (WM) | Phase 2 | Trial Discontinued | Oral | Oncology |
| Lite Strategy Inc. | Zandelisib with RITUXAN (rituximab) and VENCLEXTA (venetoclax) - (CORAL) | Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Trial Discontinued | Oral | Oncology |
| Lite Strategy Inc. | Voruciclib plus Venclexta (venetoclax) | B-Cell Malignancies or Acute Myeloid Leukemia (AML) | Phase 2 | Trial Planned | Oral | Oncology |
| Lite Strategy Inc. | Zandelisib (ME-401) - (TIDAL) | Relapsed/refractory Follicular Lymphoma (FL) Non Hodgkin Lymphoma | Phase 2 | Trial Discontinued | oral | Oncology |
